Stuttgart - Delayed Quote EUR

CytomX Therapeutics Inc (6C1.SG)

Compare
0.9245 +0.0005 (+0.05%)
As of 4:30 PM GMT+1. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
119,569.0000
101,214.0000
53,163.0000
37,312.0000
68,427.0000
Operating Expense
113,847.0000
107,698.0000
154,498.0000
153,354.0000
148,967.0000
Operating Income
5,722.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
Net Non Operating Interest Income Expense
9,367.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
Other Income Expense
-10.0000
-30.0000
340.0000
-83.0000
-27.0000
Pretax Income
15,079.0000
3,323.0000
-99,317.0000
-115,870.0000
-78,731.0000
Tax Provision
3,993.0000
3,892.0000
--
--
-13,911.0000
Net Income Common Stockholders
11,086.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Diluted NI Available to Com Stockholders
11,086.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Basic EPS
0.15
-0.01
-1.51
-1.30
-1.40
Diluted EPS
0.15
-0.01
-1.51
-1.30
-1.40
Basic Average Shares
82,339.0650
73,808.2370
65,739.8440
64,146.8480
46,145.5630
Diluted Average Shares
82,669.3060
73,808.2370
65,739.8440
64,146.8480
46,145.5630
Total Operating Income as Reported
5,722.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
Total Expenses
113,847.0000
107,698.0000
154,498.0000
153,354.0000
148,967.0000
Net Income from Continuing & Discontinued Operation
11,086.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Normalized Income
11,086.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Interest Income
9,367.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
Net Interest Income
9,367.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
EBIT
5,722.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
EBITDA
7,618.0000
-4,309.0000
-98,892.0000
-113,336.0000
-77,967.0000
Reconciled Depreciation
1,896.0000
2,175.0000
2,443.0000
2,706.0000
2,573.0000
Net Income from Continuing Operation Net Minority Interest
11,086.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Normalized EBITDA
7,618.0000
-4,309.0000
-98,892.0000
-113,336.0000
-77,967.0000
Tax Rate for Calcs
0.0003
0.0002
--
--
0.0002
12/31/2020 - 8/28/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers